3 results
The goal of this investigation is to show that Hemospray is effective in achieving initial hemostasis rates equivalent to standard of care treatment and a decreased rate of further bleed when compared to standard of care up to 72 hours after…
The primary objective is to select one of two platinum strategies to be used in this regimen for use as experimental arm in Phase III. This is a screening feasibility study addressing purely investigational approaches.
the Sponsor aims to investigate if JDQ443 will stop abnormal cell growth related to the marker KRAS G12C mutation in patients with NSCLC whose tumors have specific characteristics, such as the presence of a KRAS G12C mutation, as well as the…